A study finds low risk of malignancy from secukinumab treatment for psoriasis, psoriatic arthritis and ankylosing spondylitis patients, despite limited data.
Connor Iapoce
Advertisement
Connor Iapoce is an assistant editor for HCPLive and joined the MJH Life Sciences team in April 2021. He graduated from The College of New Jersey with a degree in Journalism and Professional Writing. He enjoys listening to records, going to concerts, and playing with his cat Squish. You can reach him at [email protected].
Articles by Connor Iapoce
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
2
AI Analysis Reveals Menopausal Hair Loss Linked to Systemic Health and Inflammation
3
Dual-Action Microneedle Patch Shows Promise for Psoriasis in Preclinical Study
4
Novel Botanical Moisturizer Demonstrates Superior Efficacy Over Metronidazole in Phase 2 Rosacea Trial
5